Business
CSL (ASX:CSL) share price dips on latest AstraZeneca news
The CSL Limited (ASX: CSL) share price is down today as the Australian Government recommended that people under 50 should not take the AstraZeneca PLC (LSE: AZN) COVID-19 vaccine.
At the time of writing, shares in the pharmaceutical giant are trading for $264.20, down 0.65%. By comparison, the S&P/ASX 200 Index (ASX: XJO) is 0.43% lower.
With the latest vaccine developments potentially impacting the country’s return to post-COVID ‘normal’, the news may be behind today’s downward trend across the stock market.
Let’s take a closer look at last night’s developments and how the CSL share price is responding.
New vaccine recommendation
In another blow to the Federal Government’s delayed vaccine rollout (and the CSL share…
-
Noosa News10 hours agoJessica Alba spotted filming spy thriller on the Gold Coast as cameras roll under iconic bridge
-
Noosa News22 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News23 hours agoFarmgate Backpackers leads with integrity amid industry challenges
-
General17 hours agoWall St futures bounce, Asia still shaky